Luc J J Derijks

5PUBLICATIONS
2CO-AUTHORS
PharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 07, 2026
Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators.

|Jul 31, 2025
Simulated Dosing Regimens of Subcutaneous Infliximab in Adults and Children with Inflammatory Bowel Disease: Exploring Switch and Initiation Strategies.

Rianne A Weersink, Ron J Keizer, Luc J J Derijks

|Dec 06, 2017
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.

E M H Schmitz, P J Boekema, J W A Straathof

|Sep 16, 2017
Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.

M M T J Broekman, M J H Coenen, G J Wanten

|Jun 09, 2017
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.

E M H Schmitz, S Benoy-De Keuster, A J L Meier

Pageof 1

Frequent Collaborators

1 joint publications

M M T J Broekman

1 joint publications

D R Wong